Pathogenic cycle between the endogenous nitric oxide synthase
inhibitor asymmetrical dimethylarginine and the
leukocyte-derived hemoprotein myeloperoxidase.

J 2011

Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.

EC, von Leitner; A KLINKE; D ATZLER; Slocum JL; N LUND et al.

Základní údaje

Originální název

Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.

Autoři

Vydání

Circulation, USA, Lippincott Williams Wilkins, 2011, 0009-7322

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 14.739

Označené pro přenos do RIV

Organizační jednotka

Přírodovědecká fakulta

DOI

https://doi.org/11/11/13/CIRCULATIONAHA.111.060541

UT WoS

000298351600023

Klíčová slova česky

arteriosclerosis endothelium inflammation leukocytes nitric oxide synthase

Klíčová slova anglicky

arteriosclerosis endothelium inflammation leukocytes nitric oxide synthase

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 5. 2012 21:18, Mgr. Michaela Pekarová, Ph.D.

Anotace

V originále

The nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and the leukocyte-derived hemoprotein myeloperoxidase (MPO) are associated with cardiovascular diseases. Activation of monocytes and polymorphonuclear neutrophils (PMNs) with concomitant release of MPO is regulated in a nitric oxide-dependent fashion. The aim of the study was to investigate a potential 2-way interaction between ADMA and MPO.

Citovat

EC, von Leitner; A KLINKE; D ATZLER; Slocum JL; N LUND; Kielstein JT; R MAAS; R SCHMIDT-HAUPT; Michaela PEKAROVÁ; O HELLWINKEL; D TSIKAS; D Alecy LG; D LAU; S WILLEMS; Lukáš KUBALA; H EHMKE; T MEINERTZ; S BLANKENBERG; E SCHWEDHELM; Gadegbeku CA; Böger RH; S BALDUS a K SYDOW. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation. USA: Lippincott Williams Wilkins, 2011, roč. 124, č. 24, s. 2735-45, 10 s. ISSN 0009-7322. Dostupné z: https://doi.org/11/11/13/CIRCULATIONAHA.111.060541.

@article{983203,
   author = {EC, von Leitner and Klinke, A and Atzler, D and JL, Slocum and Lund, N and JT, Kielstein and Maas, R and SchmidtandHaupt, R and Pekarová, Michaela and Hellwinkel, O and Tsikas, D and LG, D Alecy and Lau, D and Willems, S and Kubala, Lukáš and Ehmke, H and Meinertz, T and Blankenberg, S and Schwedhelm, E and CA, Gadegbeku and RH, Böger and Baldus, S and Sydow, K},
   article_location = {USA},
   article_number = {24},
   doi = {https://doi.org/11/11/13/CIRCULATIONAHA.111.060541},
   keywords = {arteriosclerosis endothelium inflammation leukocytes nitric oxide synthase},
   issn = {0009-7322},
   journal = {Circulation},
   title = {Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.},
   url = {http://www.ncbi.nlm.nih.gov/pubmed/22082678},
   volume = {124},
   year = {2011}
}

TY  - JOUR
ID  - 983203
AU  - EC, von Leitner - Klinke, A - Atzler, D - JL, Slocum - Lund, N - JT, Kielstein - Maas, R - Schmidt-Haupt, R - Pekarová, Michaela - Hellwinkel, O - Tsikas, D - LG, D Alecy - Lau, D - Willems, S - Kubala, Lukáš - Ehmke, H - Meinertz, T - Blankenberg, S - Schwedhelm, E - CA, Gadegbeku - RH, Böger - Baldus, S - Sydow, K
PY  - 2011
TI  - Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.
JF  - Circulation
VL  - 124
IS  - 24
SP  - 2735-45
EP  - 2735-45
PB  - Lippincott Williams Wilkins
SN  - 00097322
KW  - arteriosclerosis endothelium inflammation leukocytes nitric oxide synthase
UR  - http://www.ncbi.nlm.nih.gov/pubmed/22082678
N2  - The nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and the leukocyte-derived hemoprotein myeloperoxidase (MPO) are associated with cardiovascular diseases. Activation of monocytes and polymorphonuclear neutrophils (PMNs) with concomitant release of MPO is regulated in a nitric oxide-dependent fashion. The aim of the study was to investigate a potential 2-way interaction between ADMA and MPO.
ER  -

EC, von Leitner; A KLINKE; D ATZLER; Slocum JL; N LUND; Kielstein JT; R MAAS; R SCHMIDT-HAUPT; Michaela PEKAROVÁ; O HELLWINKEL; D TSIKAS; D Alecy LG; D LAU; S WILLEMS; Lukáš KUBALA; H EHMKE; T MEINERTZ; S BLANKENBERG; E SCHWEDHELM; Gadegbeku CA; Böger RH; S BALDUS a K SYDOW. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. \textit{Circulation}. USA: Lippincott Williams Wilkins, 2011, roč.~124, č.~24, s.~2735-45, 10 s. ISSN~0009-7322. Dostupné z: https://doi.org/11/11/13/CIRCULATIONAHA.111.060541.

Přehled o publikaci